Exploratory trial of a combination therapy of Gemcitabine, S1 and immunotherapy against pancreatic cancer. - Exploratory trial of a combination therapy of Gemcitabine, S1 and immunotherapy against pancreatic cancer.

Department of Gastroenterology and Hepatology, School of Medicine, Kochi University0 个研究点目标入组 6 人开始时间: 2017年5月31日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with uncontrollable infectious diseases (including active Tuberculosis) 2) patients with severe complications (malignant lypertension, severe congestive heart failure, severe colonary in sufficiency, myocardial, infarction within three months, terminal, stage of liver cirrhousis, uncontrollable diabetes mellitus, severe pulmonary fibrosis, active interstitial pneumonitis, etc.) 3) patients with serious comorbidities (generally those of NCI-CTC ver 3.0 grade 3 or higher) 4) patients who have been under parenteral nutrition for more than 24 hours due to impairment of digestive organs. 5) liver metastasis occupying more than 1/3 of the liver 6) Patients with active concomitant malignancy 7) patients with hematopoietic malignancies including MDS, MDS/MPD, CML 8) patients who have received bone marrow or hematopoietic stem cell transplantation 9) pregnant women, breast feeding mothers 10) patients with serious psychological disorders 11) patients whose participation to the study is considered inappropriate by the doctors for various reasons.

发起方

Department of Gastroenterology and Hepatology, School of Medicine, Kochi University